Aptamer announces upcoming contracts as it seeks finance
York biotech Aptamer has revealed details of four contracts from its pipeline worth a total of £507,000.
The firm is struggling after a “difficult 12 months”, it said in a statement to the London Stock Exchange on Tuesday, with cash reserves at the end of June standing at £200,000. It said then that it needed an urgent short-term cash injection to keep trading.
The board is still reviewing financing options and managing working capital, and reiterated it cannot be certain it will get the finance it needs.
The four deals are:
- Developing its Optimer binders to enable new ways to purify gene therapies for a top 10 pharma company.
- Developing Optimer binders to target neurodegenerative disease to support a US gene therapy firm.
- Generating Optimer binders to help a US genetic medicine firm target two viruses, with potential for further downstream licensing revenues.
- A follow-on deal with a US vaccine development company following positive results in an earlier project, which will see Aptamer deevelop Optimer binders to improve slectivity in viral targets, again with further licensing revenue potential.
